Entero Healthcare Latest News: Entero Healthcare Surges +65.30 (6.00%) Today: Key Reasons and What Analysts Say
- June 24, 2026
- Posted by: Harsh Piplani
- Category: News
Entero Healthcare latest news: NSE: ENTERO Rs 1,153.30 (latest). Up +65.30 (6.00%). 52W high Rs 1,390. 52W low Rs 944. MCap Rs ~5,000 Cr. P/E 43.40x.
Entero Healthcare Latest News is driving investor attention today as Entero Healthcare Solutions Ltd (NSE: ENTERO) surged +65.30 (6.00%) to emerge as one of the top gainers on the NSE. The Healthcare Distribution and Supply Chain company has a 52-week high of Rs 1,390 and has delivered a -4.56% return over the past year.
This Entero Healthcare latest news analysis covers the key reasons behind today’s sharp rally, what market analysts are tracking, the next price targets to watch, and the key risks investors should consider before chasing the move.
Click Here – Get Free Investment Predictions
About Entero Healthcare: Company Overview
India’s top-three healthcare supply chain solutions specialist by revenue, incorporated in 2018 and headquartered in New Delhi. Entero Healthcare distributes pharmaceutical, surgical, and medical device products to hospitals, retail pharmacies, and healthcare clinics across India. The company has been rapidly expanding through acquisitions in the MedTech segment and targets MedTech revenue crossing Rs 1,000 crore in FY27. FY26 revenue was Rs 6,591 crore, up 29.35% year-on-year.
| Metric | Value |
|---|---|
| CMP (Latest) | Rs 1,153.30 |
| Today’s Gain | +65.30 (6.00%) |
| 52-Week High | Rs 1,390 |
| 52-Week Low | Rs 944 |
| Market Cap | Rs ~5,000 Cr |
| P/E Ratio (TTM) | 43.40x |
| 1-Year Return | -4.56% |
| NSE Symbol | NSE: ENTERO |
Why Is Entero Healthcare Rising Today? Key Reasons in Entero Healthcare Latest News
Three key developments are driving today’s Entero Healthcare latest news surge of +65.30 (6.00%).
Strong Buy Consensus From 4 Analysts With Rs 1,516 Average Target
Entero Healthcare carries a Strong Buy consensus rating from all 4 analysts covering the stock, with an average 12-month target of Rs 1,516.75, a high estimate of Rs 1,590, and a low estimate of Rs 1,477. The Simply Wall St intrinsic value model estimates Rs 1,658 per share. At the current price, the average analyst target implies approximately 31% upside. Today’s 6% surge reflects institutional accumulation at a discount to the analyst target range, particularly following the stock’s recent correction from Rs 1,390 peak levels.
Q4 FY26 Revenue Surged 42.63% YoY and MedTech Scaling Strongly
Entero Healthcare’s Q4 FY26 revenue of Rs 1,909.93 crore grew 42.63% year-on-year. Full-year FY26 revenue of Rs 6,591 crore (up 29.35%) and net profit of Rs 115.04 crore (up 21.32%) demonstrate the company’s ability to scale revenue consistently. The MedTech segment is expected to cross Rs 1,000 crore in FY27, adding a higher-margin revenue stream. Management confirmed FY27 operating cash flow improved to Rs 96.2 crore.
Strategic Acquisitions Accelerating Healthcare Distribution Consolidation
Entero Healthcare completed the acquisition of Vishal Surgicals and was approved to acquire Anand Chemiceutics (51% stake, Rs 230 crore) as part of its MedTech expansion strategy. The company has acquired multiple regional pharma distributors to consolidate India’s fragmented healthcare distribution market. ESOP allotments and director reappointments at the Q4 FY26 board meeting signal strong management confidence in the long-term growth trajectory.
Use the Univest Screener to Track Live Price and Key Data
What Market Analysts Are Saying About Entero Healthcare Latest News
4 analysts all have Strong Buy ratings on Entero Healthcare with an average 12-month target of Rs 1,516.75. The intrinsic value estimate from Simply Wall St is Rs 1,658 per share. The company is forecast to post FY27 EPS of Rs 37.76 versus FY26 EPS of Rs 26.44, representing 43% earnings growth. Revenue is expected to grow 20% per year over the next two years. The MedTech segment is the key upside catalyst.
Ankit Jaiswal, Senior Research Analyst at Univest, notes that the Entero Healthcare latest news surge of +65.30 (6.00%) today reflects genuine fundamental strength. He advises investors who missed the initial move to wait for the stock to consolidate above the Rs 1,050 support zone before considering a fresh entry, rather than chasing the price at the peak of a single-day move.
Kunal Singla, Research Analyst at Univest, observes that the Entero Healthcare latest news breakout today is technically significant, with the stock establishing a new near-term high on strong volume. He notes that as long as the stock holds above Rs 1,050 on weekly closes, the bullish structure remains intact and the Rs 1,350 to 1,516 zone is achievable over the coming weeks.
Entero Healthcare Latest News: Next Price Targets and Key Levels
Following today’s strong rally, the key price levels for the Entero Healthcare latest news story are:
| Level | Price (Rs) | Significance |
|---|---|---|
| Current Price (After Rally) | 1,153.30 | Post-gain level after +65.30 (6.00%) today |
| Key Support | 1,050 | Weekly close support; pullbacks here = accumulation zone |
| Near-Term Target | 1,350 to 1,516 | Based on analyst consensus and technical momentum |
| 52-Week High | 1,390 | Full recovery reference level |
These are technical reference levels. They are not guaranteed targets. Please consult a SEBI-registered financial advisor before making any investment decision in Entero Healthcare.
Key Risks to Monitor Even After Today’s Rally
Thin Profit Margins and Integration Risk From Multiple Acquisitions
Entero Healthcare operates in pharmaceutical distribution with historically thin margins (approximately 1.6 to 1.7% net profit margins). Scaling profitability while integrating multiple acquired entities increases execution risk. Any integration delay could dampen the earnings growth trajectory analysts are projecting for FY27.
GST Changes and Regulatory Risk in Pharma Distribution
Management highlighted GST-related challenges and delays in closing new deals in FY26. The pharma distribution sector is subject to regulatory changes by the NPPA that can impact trade margins.
Competitive Intensity in Healthcare Distribution Consolidation
India’s pharma distribution market is attracting multiple consolidators. Increased competition for acquisition targets could drive up acquisition prices and reduce Entero’s ability to extract synergies at reasonable capital costs.
Conclusion
The Entero Healthcare latest news surge of +65.30 (6.00%) today is driven by strong buy consensus from 4 analysts with rs 1,516 average target alongside strong fundamental support. Ankit Jaiswal of Univest advises disciplined entry strategy rather than chasing the current price, with Rs 1,050 as the key support reference. Kunal Singla observes the bullish structure supports a move towards Rs 1,350 to 1,516 on weekly closes above support. Investors should track the Nifty Pharma index for broader sector signals. Please consult a SEBI-registered investment advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App to track Entero Healthcare live price and receive expert daily stock research.
Frequently Asked Questions on Entero Healthcare Latest News
What is Entero Healthcare latest news today?
Ans. Entero Healthcare latest news is that the stock gained Rs 65.30 (6.00%) to Rs 1,153.30, one of the top gainers today. The rally is driven by strong analyst conviction (4 analysts, all Strong Buy, average target Rs 1,516.75), robust FY26 results (revenue +29.35%, profit +21.32%), and institutional accumulation at a discount to the analyst consensus target.
Why is Entero Healthcare share price rising today?
Ans. Entero Healthcare is rising due to strong institutional buying based on analyst targets significantly above the current price, Q4 FY26 revenue growing 42.63% YoY to Rs 1,910 crore, and the MedTech segment on track to cross Rs 1,000 crore in FY27. The stock was trading at a significant discount to its analyst average target of Rs 1,516.75.
What is the analyst target for Entero Healthcare?
Ans. The average 12-month analyst target for Entero Healthcare is Rs 1,516.75 based on 4 analysts, all with Strong Buy ratings. The high target is Rs 1,590 and the low is Rs 1,477. The Simply Wall St intrinsic value model estimates Rs 1,658 per share. FY27 EPS is forecast at Rs 37.76 versus FY26 Rs 26.44, representing 43% earnings growth.
What is Entero Healthcare’s FY26 performance?
Ans. Entero Healthcare’s FY26 revenue grew 29.35% to Rs 6,591 crore and net profit grew 21.32% to Rs 115 crore. Q4 FY26 was the strongest quarter with revenue of Rs 1,910 crore (+42.63% YoY). The MedTech segment is expected to cross Rs 1,000 crore in FY27.
What is Entero Healthcare’s market cap and valuation after today’s rally?
Ans. After today’s +65.30 (6.00%) gain, Entero Healthcare has a market capitalisation of approximately Rs ~5,000 crore and trades at a P/E ratio of 43.40x. The stock has a 52-week high of Rs 1,390 and a 52-week low of Rs 944. Verify all data at nseindia.com before making any investment decision.
Is Entero Healthcare a buy after today’s rally?
Ans. Whether Entero Healthcare is a buy after today’s +65.30 (6.00%) rally depends on your investment horizon and risk tolerance. The fundamental drivers behind today’s move are real and medium-term positive. However, buying after a large single-day move carries short-term correction risk. Univest analysts recommend waiting for consolidation above Rs 1,050 before initiating fresh positions. This is not investment advice. Consult a SEBI-registered financial advisor.
